TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, NTPs and mRNA capping analogs. TriLink has scale-up expertise and unique mRNA, oligonucleotide & plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs.
Biopharma companies turn to TriLink as a critical supplier of modified nucleic acids and as a CDMO partner to help them move from early research into clinical trials. TriLink’s proprietary CleanCap® mRNA co-transcriptional capping technology simplifies mRNA manufacturing by removing additional enzymatic steps, resulting in high capping efficiency and improved yields over traditional co-transcriptional capping methods.
TriLink’s CDMO services offer a range of manufacturing grade products from discovery-grade (RUO) to its customizable intermediate-grade - GMPLink™ to full GMP-grade with scale-up and technology transfer expertise. With its recent facility expansion to increase cGMP capacity, TriLink provides support from initial research phases to the production of material for use in clinical trials. TriLink operates a quality system in compliance with ICH Q7, Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Section 19, APIs for Use in Clinical Trials, and ISO 9001:2015 standards.
TriLink has been a pioneer in nucleic acid synthesis & manufacturing since its inception in 1996. With product and service offerings and expertise that have adapted to customer needs over the decades, TriLink remains committed to taking on challenges others simply will not. TriLink continues to expand its cGMP and general mRNA, oligonucleotide & plasmid manufacturing capacity at its new San Diego global headquarters to support therapeutic, vaccine and diagnostic customers.
Founded in May in San Diego, California. By year-end, TriLink moves into first commercial lab space, begins shipping oligonucleotides, and hires first employees.
Obtains license to synthesize radioactive compounds. TriLink quickly becomes the industry leader and one of the only companies in the world to successfully manufacture radio-labeled oligos.
First customer-written paper citing TriLink products is published in the Journal of Immunology by David Broide et al., Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice.
Expands into nucleoside triphosphates. Cofounds Solulink®, a company focused on unique bioconjugation chemistries. Outgrows first lab and expands to Nancy Ridge site. First paper under TriLink corporate name is published.
Company continues to experience remarkable growth and expands to a 40,000 square foot building that served as the corporate headquarters.
Receives first of four SBIR grants for chemically modified primers and NTPs for improved hot-start PCR, the basis of the CleanAmp® product line.
Proven pre-clinical oligo production leads to first alliance partnership with large therapeutic oligo CMO, enabling customers to easily transition from R&D to clinical trials.
Leverages expertise with complicated nucleic acids and begins IVT production of long RNA and mRNA for use in pharmaceutical research and development. First patent for CleanAmp® is granted.
Receives ISO 9001 certification. Opens state-of-the-art cGMP manufacturing facility and expands into mRNA and oligonucleotide therapeutics. Secures contract for synthesis of Ebola vaccine with Battelle. Awarded patents for proprietary CleanTag® technology.
Publications citing TriLink products exceeds 6,000. Adds gram scale mRNA production and expands mRNA purification offerings. Launches CleanTag® Small RNA Library Prep kits. Cofounds ETAGEN, a company focused on gene editing technologies, with Tod Woolf.
Strategic investment by Maravai LifeSciences.
Launches CleanCap® - a patented mRNA capping method that makes remarkable improvements over existing technology.
Receives ISO 9001:2015 certification.
TriLink & Maravai move to new global headquarters. Space includes 105,000 sq. ft. facility space with 50,000 sq. ft. of custom manufacturing space, including 5 cGMP suites.
Two patents granted surrounding CleanCap® technology. The patents cover capped trinucleotide primers and capped tetranucleotide primers not limited to any particular sequences.
Expands services to include plasmid manufacturing
TriLink BioTechnologies Expands its Intellectual Property Portfolio with European Patent for its CleanCap® technology
Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides
